Dermal Fillers May Induce Late-Onset Adverse Skin Reactions In Patients Under Braf Inhibitors

Histiocytoses are disorders characterised by inflammation and the accumulation of cells derived from the monocyte and macrophage lineages, which results in tissue damage. Considerable advances in the understanding of their genetics have led to an increased clinical recognition of these conditions, and fuelled futher insights into their pathogenesis(1). Almost 70% of patients affected by Erdheim-Chester disease (ECD), a rare non-Langerhans cell histiocytosis, have the somatic V600E mutation of the BRAF gene(2). BRAF and MEK inhibitors can be efficacious for treating ECD, particularly in cases of life-threatening manifestations(3).